• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.

作者信息

Kubota Keisuke, Katayama Atom, Takeshita Yutarou, Nozaki Koji, Ueda Tetsuya, Imamura Kazuhiro, Hiki Naoki, Nomura Sachiyo, Kaminishi Michio, Mafune Ken-Ichi

机构信息

Department of Surgery, The International University of Health and Welfare Mita Hospital, Mita, Tokyo, Japan.

出版信息

Dig Dis Sci. 2007 Jul;52(7):1725-9. doi: 10.1007/s10620-006-9092-6. Epub 2007 Feb 15.

DOI:10.1007/s10620-006-9092-6
PMID:17546507
Abstract
摘要

相似文献

1
Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.甲磺酸伊马替尼对一名外显子11存在c-kit突变的转移性胃肠道间质瘤患者的疗效。
Dig Dis Sci. 2007 Jul;52(7):1725-9. doi: 10.1007/s10620-006-9092-6. Epub 2007 Feb 15.
2
[Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].[继发性伊马替尼耐药胃肠道间质瘤的分子与组织学特征]
Zhonghua Bing Li Xue Za Zhi. 2013 Jan;42(1):42-3. doi: 10.3760/cma.j.issn.0529-5807.2013.01.009.
3
Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.一名无法切除的十二指肠胃肠道间质瘤患者对甲磺酸伊马替尼产生继发性耐药，该患者c-kit原癌基因的第9、11、13或17外显子无突变。
J Gastroenterol. 2004 Sep;39(9):904-5. doi: 10.1007/s00535-003-1409-z.
4
A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.一例胃肠道间质瘤中发现一种新的原发性KIT外显子9单核苷酸替换c.1427G>T（p.Ser476Ile）
Virchows Arch. 2010 Nov;457(5):623-5. doi: 10.1007/s00428-010-0987-4. Epub 2010 Oct 5.
5
[Consensus on the medical treatment of gastrointestinal stromal tumors].[胃肠间质瘤的医学治疗共识]
Zhonghua Zhong Liu Za Zhi. 2007 Nov;29(11):875-7.
6
Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.不吉利的数字13？KIT基因第13外显子突变在胃肠道间质瘤中的不同效应。
Mol Oncol. 2008 Aug;2(2):161-3. doi: 10.1016/j.molonc.2008.05.002. Epub 2008 May 10.
7
[KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].[胃肠道间质瘤病理诊断与靶向治疗中的KIT突变分析：最新进展]
Zhonghua Bing Li Xue Za Zhi. 2007 Jul;36(7):440-3.
8
C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.C-KIT 突变与中国晚期胃肠间质瘤患者对伊马替尼的反应密切相关。
Med Oncol. 2012 Dec;29(5):3039-45. doi: 10.1007/s12032-012-0308-7. Epub 2012 Jul 20.
9
In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.伊马替尼对17外显子型c-kit基因敲入小鼠盲肠GIST样肿瘤进展的体内作用。
Lab Invest. 2009 Oct;89(10):1161-8. doi: 10.1038/labinvest.2009.78. Epub 2009 Jul 27.
10
Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.长期接受甲磺酸伊马替尼治疗的复发性胃肠道间质瘤中的继发性c-kit突变：一例报告
Surg Today. 2008;38(1):65-7. doi: 10.1007/s00595-007-3559-8. Epub 2007 Dec 24.

本文引用的文献

1
Biology of gastrointestinal stromal tumors.胃肠道间质瘤的生物学
J Clin Oncol. 2004 Sep 15;22(18):3813-25. doi: 10.1200/JCO.2004.05.140.
2
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.KIT（CD117抗原）免疫反应阴性的胃肠道间质瘤（GISTs）
J Pathol. 2004 Apr;202(4):430-8. doi: 10.1002/path.1546.
3
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.伊马替尼治疗的胃肠道间质瘤患者的血清KIT和KIT配体水平
Blood. 2004 Apr 15;103(8):2929-35. doi: 10.1182/blood-2003-10-3443. Epub 2004 Jan 8.
4
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.转移性胃肠道间质瘤患者的激酶突变与伊马替尼反应
J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190.
5
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.格列卫在胃肠道间质瘤中的反应标志物及分子作用机制
Mol Cancer Ther. 2003 Aug;2(8):699-709.
6
Elevated (> or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases.MIB-1增殖指数升高（≥10%）与胃间质瘤患者的不良预后相关：一项35例病例的研究。
Dig Dis Sci. 2002 Oct;47(10):2247-53. doi: 10.1023/a:1020187211376.
7
Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate).接受格列卫（甲磺酸伊马替尼）治疗的胃肠道间质瘤（GISTs）肝转移灶中的囊性改变
AJR Am J Roentgenol. 2002 Oct;179(4):1059-62. doi: 10.2214/ajr.179.4.1791059.
8
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.甲磺酸伊马替尼在晚期胃肠道间质瘤中的疗效与安全性。
N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461.
9
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.伊马替尼（STI571）治疗转移性胃肠道间质瘤的安全性和有效性：一项I期研究。
Lancet. 2001 Oct 27;358(9291):1421-3. doi: 10.1016/s0140-6736(01)06535-7.
10
Gastrointestinal stromal tumor workshop.胃肠道间质瘤研讨会
Hum Pathol. 2001 Jun;32(6):578-82. doi: 10.1053/hupa.2001.25484.